We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Bausch + Lomb (BLCO - Free Report) will announce quarterly earnings of $0.35 per share in its forthcoming report, representing an increase of 40% year over year. Revenues are projected to reach $1.38 billion, increasing 8.1% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Bausch + Lomb metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenues- Vision Care' will reach $780.35 million. The estimate suggests a change of +7.9% year over year.
The consensus estimate for 'Revenues- Pharmaceuticals' stands at $355.40 million. The estimate points to a change of +9% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Product sales' should come in at $1.37 billion. The estimate indicates a year-over-year change of +7.6%.
The combined assessment of analysts suggests that 'Revenues- Other revenues' will likely reach $5.00 million.
The consensus among analysts is that 'Revenues- Surgical' will reach $248.04 million. The estimate suggests a change of +7.4% year over year.
Bausch + Lomb shares have witnessed a change of -0.8% in the past month, in contrast to the Zacks S&P 500 composite's -1.7% move. With a Zacks Rank #2 (Buy), BLCO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Bausch + Lomb (BLCO - Free Report) will announce quarterly earnings of $0.35 per share in its forthcoming report, representing an increase of 40% year over year. Revenues are projected to reach $1.38 billion, increasing 8.1% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Bausch + Lomb metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenues- Vision Care' will reach $780.35 million. The estimate suggests a change of +7.9% year over year.
The consensus estimate for 'Revenues- Pharmaceuticals' stands at $355.40 million. The estimate points to a change of +9% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Product sales' should come in at $1.37 billion. The estimate indicates a year-over-year change of +7.6%.
The combined assessment of analysts suggests that 'Revenues- Other revenues' will likely reach $5.00 million.
The consensus among analysts is that 'Revenues- Surgical' will reach $248.04 million. The estimate suggests a change of +7.4% year over year.
View all Key Company Metrics for Bausch + Lomb here>>>Bausch + Lomb shares have witnessed a change of -0.8% in the past month, in contrast to the Zacks S&P 500 composite's -1.7% move. With a Zacks Rank #2 (Buy), BLCO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .